Candel Therapeutics’ CAN-2409 Earns FDA Fast Track Designation, Stock Rises
Candel Therapeutics, a leading clinical-stage biopharmaceutical company specializing in the development of multimodal biological immunotherapies for cancer, announced that the US Food and Drug Administration
